| Xu Jinbing,Huang Wei,Guo Huagui,Huang Shiqing,Tang Chaohua,Liang Jiaquan,Li Xuesong,Clinical study on the treatment of depression with venlafaxine under the guidance of pharmacogenomics testing[J].SICHUAN MENTAL HEALTH,2021,34(3):239-242 |
| Clinical study on the treatment of depression with venlafaxine under the guidance of pharmacogenomics testing |
DOI：10.11886/scjsws20210124001 |
| English keywords:Pharmacogenomics testing Venlafaxine Depression Individualized treatment |
| Fund projects:2019年佛山市自筹经费类科技计划项目（医学类科技攻关项目）（项目名称：个体化用药基因检测对改善抑郁障碍药物治疗预后作用研究，项目编号：1920001001782） |
|
| Hits: |
| Download times: |
| English abstract: |
| Objective To investigate the efficacy and safety of venlafaxine in the treatment of depression under the guidance of pharmacogenomics testing， and to provide references for individualized medication.Methods A total of 66 patients who met the diagnostic criteria of International Classification of Diseases， tenth edition （ICD-10） for depressive episode were included in the study. Patients who were recommended to be treated with venlafaxine in the pharmacogenomics testing report were divided into study group （n=32）， and those who were decided to be treated with venlafaxine by doctors after consultation with patients were divided into control group （n=34）. At the baseline and the end of the 2nd， 4th， 6th and 8th weekend of treatment， Hamilton Depression Scale-24 item （HAMD-24） was adopted to evaluate the clinical efficacy. Meanwhile， Sheehan Disability Scale （SDS） was applied to measure the social function of patients at the baseline and the end of the 8th weekend of treatment. After treatment， Treatment Emergent Symptom Scale （TESS） was used to assess the incidence of adverse reactions.Results At the end of the 4th， 6th and 8th weekend of treatment， HAMD-24 scores in the study group were all lower than those in the control group， with statistical differences （t=2.344， 4.316， 5.760， P<0.05 or 0.01）. At the end of the 8th weekend of treatment， SDS score of the study group was lower than that of the control group， with statistical difference （t=2.173， P<0.05）. The adverse reaction rate in the study group was lower than that in the control group， with statistical difference （χ2=5.720， P<0.05）.Conclusion Treatment of depression with venlafaxine based on pharmacogenetic testing is an effective and safe way to alleviate the depression symptoms in patients. |
| View Full Text
View/Add Comment Download reader |
| Close |